Navigation Links
Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
Date:2/8/2010

LAWRENCEVILLE, N.J., Feb. 8 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Michael H. Richardson has joined the company as Vice President, Commercial Operations for the newly formed Orphan Drug Business Unit. Donald A. Fishbein assumes the same role for the Ophthalmic Business Unit. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

Mr. Richardson holds responsibility of the company's orphan drug portfolio, which includes well-established specialty pharmaceuticals treating a range of rare and life-threatening conditions (Mephyton®, Edecrin®, Sodium Edecrin®, Cuprimine®, Syprine®, Demser®).  

Mr. Richardson possesses nearly 20 years of experience in pharmaceutical marketing, sales, product planning and business development. Prior to joining Aton, he was a Group Director of Marketing and Senior Director of Worldwide Product Planning for Cephalon. In those roles, Mr. Richardson was responsible for the successful launch of multiple products.

"With both product and corporate management experience, Michael Richardson brings tremendous commercial leadership to Aton Pharma," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is well rounded in all aspects of pharmaceutical marketing and preparing new products for launch. This experience will provide tremendous value to the company as we expand our orphan drug portfolio."

Prior to Cephalon, Mr. Richardson was a Director of Global Strategic Marketing at Johnson & Johnson where he worked on optimizing the life cycle of several strategic pro
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
2. Octapharma Accepting Applications for Research Grants Through March 31
3. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
4. Possible pharmacological target(s) identified in pediatric OSA
5. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
6. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
7. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
8. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
9. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
10. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
11. Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led a ... available tests that better incorporate personalized medicine into diagnosing the condition. , Their ... published in the July issue of the scientific journal Thyroid . The ...
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... Virginia (PRWEB) , ... July 06, 2015 , ... ... choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ... For a particular demographic, however, fat reduction has become more than a way ...
(Date:7/6/2015)... OH (PRWEB) , ... July 06, 2015 , ... ... the proper reimbursement for radiology services and ADVOCATE is leading the transition. ADVOCATE, ... their coding expertise with their Top 10 Tips for ICD-10. The ten tips ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN ... same cancer. , “Receiving a cancer diagnosis is often the most traumatic experience ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... SALT LAKE CITY, Dec. 15 The new compact LifeSpan TR200 ... ), was highly praised by treadmill review groups in recent ... treadmill received awards for Best New Treadmill, Recommended Unique Design, and ... is designed for light use walking indoors in small workout spaces. ...
... study links chronic obstructive pulmonary disease, or COPD, with ... activate the body,s immune system. The University ... awareness of the immune system,s role in COPD, a ... million Americans with wheezing, shortness of breath, chest tightening ...
... increases risk in teens, study suggests , TUESDAY, Dec. ... obese increases the risk of obstructive sleep apnea, but ... younger children, Australian researchers have found. , In sleep ... 18, who were referred for evaluation of snoring and ...
... potential for injury when doctors decide benefits of imaging ... -- MRI scans can pose a serious risk to ... and Drug Administration researchers exposed pacemakers to a simulated ... produced at the tip of the pacemaker lead, where ...
... , ... Reportlinker.com announces that a new market research ... In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. ... , http://www.reportlinker.com/p0167482/In-Vitro-Diagnostic-Substance-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html , The newly published ...
... , , NEW YORK, ... new market research report is available in ... Cardiovascular Diseases Therapeutics - Market Forecasts to ... Analysis , http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html , ...
Cached Medicine News:Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Immune cell activity linked to worsening COPD 2Health News:Immune cell activity linked to worsening COPD 3Health News:Puberty May Trigger Sleep Apnea in Overweight Kids 2Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17
(Date:7/6/2015)... DUBLIN , June 29, 2015 ... the addition of the "Pharmaceutical Packaging Market in ... The pharmaceutical packaging market in North ... 5.31% over the period 2014-2019. International ... bodies on drug manufacturers, which in turn fuels adoption ...
(Date:7/6/2015)... July 6, 2015 E-QURE Corp (OTCQB: EQUR), ... live at VirtualInvestorConferences.com on July 9, 2015. ... http://tinyurl.com/e-qure-presentation This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
(Date:7/6/2015)... ATLANTA , July 6, 2015 Celtaxsys, ... anti-inflammatory therapeutics, including those with rare and orphan inflammatory ... from the U.S. Food and Drug Administration (FDA) to ... drug candidate, acebilustat (CTX-4430), in adult CF patients in ... in Europe will be filed ...
Breaking Medicine Technology:North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
... Monoclonal antibody method for HbA1c provides outstanding ... 99% agreement with the HPLC method(1) , ... a CV of 2.6%* means your results ... (NGSP) certified method, as recommended by the ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: